NovaBridge Biosciences (NBP) Free Cash Flow (2019 - 2025)

NovaBridge Biosciences (NBP) reported Free Cash Flow of -$14.6 million for Q4 2025, down 33.77% year-over-year from -$22.0 million in Q4 2024, and down 893.69% quarter-over-quarter from $1.8 million in Q3 2025.

NovaBridge Biosciences (NBP) Free Cash Flow (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has 4 years of Free Cash Flow data on file, last reported at -$14.6 million in Q4 2025.

  • Free Cash Flow for Q4 2025 came in at -$14.6 million, down 33.77% year-over-year; the trailing twelve-month figure through Dec 2025 was -$12.8 million (down 412.74% YoY), and the FY2025 annual result was -$20.6 million, up 60.87% from the prior year.
  • Free Cash Flow retreated to -$14.6 million in Q4 2025 per NBP's latest filing, from $1.8 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $8.4 million in Q3 2024 and troughed at -$14.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
2 Belite Bio 55,234.00 Bn 55,234.00 Bn - -
3 Quantum Biopharma 17,823.14 Bn 17,823.14 Bn - -1.67 Mn
4 Legend Biotech 3,624.50 Bn 3,624.21 Bn 242.10 Mn -12.20 Mn
5 Akari Therapeutics 1,745.73 Bn 1,745.73 Bn - -2.49 Mn
6 Evaxion A 1,540.85 Bn 1,540.84 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 112.57 Bn 105.33 Bn 2.59 Bn 1.29 Bn
9 Abivax 93.46 Bn 93.46 Bn - 63,220.27
10 NovaBridge Biosciences 331.49 Mn 120.65 Mn - -14.60 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -14.60 Mn
Dec 31, 2025 -14.60 Mn
Sep 30, 2025 1.84 Mn
Sep 30, 2025 1.84 Mn
Dec 31, 2024 -10.91 Mn
Dec 31, 2024 -10.91 Mn
Sep 30, 2024 8.42 Mn
Sep 30, 2024 8.42 Mn
Dec 31, 2020 -1.93 Mn
Dec 31, 2020 -1.93 Mn
Sep 30, 2020 668,359.95
Sep 30, 2020 668,359.95
Dec 31, 2019 -2.39 Mn
Dec 31, 2019 -2.39 Mn